DJIA 17,810.06 91.06 0.51%
NASDAQ 4,712.97 11.10 0.24%
S&P 500 2,063.50 10.75 0.52%
market minute promo

Medivation, Inc. (NASDAQ: MDVN)

109.28 -1.97 (-1.77%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

MDVN $109.28 -1.77%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $112.73
Previous Close $111.25
Daily Range $108.44 - $112.85
52-Week Range $54.37 - $113.61
Market Cap $8.5B
P/E Ratio 78.35
Dividend (Yield) $0.00 (0.0%)
Volume 782,754
Average Daily Volume 1,042,709
Current FY EPS $2.56





Medivation, Inc. (MDVN) Description

A biopharmaceutical company engaged in the acquisition, research and development of promising medical technologies. Website:

News & Commentary Rss Feed

Should Johnson & Johnson Buy Medivation Inc.?

Johnson & Johnson's top-selling prostate cancer treatment is facing a stiff challenger in Medivation's Xtandi, but an acquisition may not be in the cards.

MDVN January 2017 Options Begin Trading

Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog

Update: Medivation Q3 Earnings

The Next Chapter in Dendron's Troubled History: Chapter 11 Bankruptcy

5 Prescription Drugs Selling Like Hot Cakes

Gilead Sciences, Biogen, Johnson & Johnson, Medivation, and Celgene have some of the fastest growing drugs in biotechnology.

Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog

Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog

Major Upgrades And Downgrades In Friday's Market Action

3 Drugs Stocks Pushing The Industry Higher

Medivation's (MDVN) CEO David Hung on Q3 2014 Results - Earnings Call Transcript

See More MDVN News...

MDVN's Top Competitors

MDVN $109.28 (-1.77%)
Current stock: MDVN
TMO $126.54 (1.57%)
Current stock: TMO
ILMN $185.83 (-0.23%)
Current stock: ILMN
WAT $115.84 (-0.08%)
Current stock: WAT